

FINAL PROGRAM

# VIRTUAL XVIII NIBIT MEETING

COVID-19 at the intersection  
between cancer, immunity and immunotherapy



[www.nibit.org](http://www.nibit.org)

October 15-16, 2020

# UNDER THE AUSPICES OF



# ACKNOWLEDGMENTS



# NIBIT SCIENTIFIC COMMITTEE AND FACULTY

## NIBIT SCIENTIFIC COMMITTEE

**Paolo Ascierto** (Napoli, Italy)  
**Matteo Bellone** (Milano, Italy)  
**Marco Bregni** (Milano, Italy)  
**Vincenzo Bronte** (Verona, Italy)  
**Mario Paolo Colombo** (Milano, Italy)  
**Massimo Di Nicola** (Milano, Italy)

**Pier Francesco Ferrucci** (Milano, Italy)  
**Marina Garassino** (Milano, Italy)  
**Paola Nisticò** (Roma, Italy)  
**Antonio Rosato** (Padova, Italy)  
**Vincenzo Russo** (Milano, Italy)  
**Antonio Sica** (Milano, Italy)

## FACULTY

**Raza Ali** - University of Cambridge (Cambridge, UK)  
**Andrea Alimonti** - ETH Zurich Institute of Oncology Research (Zurich, Switzerland)  
**Paola Allavena** - Humanitas Research Hospital (Rozzano - MI, Italy)  
**Paolo Ascierto** - Istituto Nazionale dei Tumori "G. Pascale" (Napoli, Italy)  
**Vincenzo Barnaba** - Università La Sapienza (Roma, Italy)  
**Matteo Bellone** - IRCCS Ospedale San Raffaele (Milano, Italy)  
**Attilio Bondanza** - Novartis Institutes for Biomedical Research (Basel, Switzerland)  
**Marco Bregni** - IRCCS Ospedale San Raffaele (Milano, Italy)  
**Vincenzo Bronte** - Università degli Studi di Verona (Verona, Italy)  
**Giulia Casorati** - IRCCS Ospedale San Raffaele (Milano, Italy)  
**Marco Cassatella** - Università degli Studi di Verona (Verona, Italy)  
**Giulio Cavalli** - Università Vita-Salute San Raffaele (Milano, Italy)  
**Mario Paolo Colombo** - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)  
**Karin de Visser** - Netherlands Cancer Institute (Amsterdam, The Netherlands)  
**Paolo Dellabona** - IRCCS Ospedale San Raffaele (Milano, Italy)  
**Giuseppe Di Lucca** - IRCCS Ospedale San Raffaele (Milano, Italy)  
**Massimo Di Nicola** - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)  
**Claudio Dogliani** - Università Vita-Salute San Raffaele (Milano, Italy)  
**Pier Francesco Ferrucci** - Istituto Europeo di Oncologia IEO (Milano, Italy)  
**Wolf-Herman Fridman** - Université Paris Descartes (Paris, France)  
**Enzo Galligioni** - Fondazione Pezcoller (Trento, Italy)  
**Alessandra Gennari** - Università del Piemonte Orientale (Novara, Italy)  
**Antonio Lanzavecchia** - Institute for Research in Biomedicine (Bellinzona, Switzerland)  
**Ann Leen** - Baylor College of Medicine (Houston, USA)  
**Paola Nisticò** - IFO Istituto Regina Elena (Roma, Italy)  
**Drew Pardoll** - John Hopkins Bloomberg - Kimmel Institute for Cancer Immunotherapy (Baltimore, USA)  
**Concetta Quintarelli** - Ospedale Pediatrico Bambino Gesù (Roma, Italy)  
**Maria Rescigno** - Humanitas University (Milano, Italy)  
**Cliona Rooney** - Texas Children's Hospital (Houston, USA)  
**Antonio Rosato** - Università degli Studi di Padova (Padova, Italy)  
**Vincenzo Russo** - IRCCS Ospedale San Raffaele (Milano, Italy)  
**Catherine Sautes-Fridman** - UPMC Sorbonne Université (Paris, France)  
**Antonio Sica** - Humanitas Research Hospital (Rozzano - MI, Italy)  
**Suzanne Topalian** - John Hopkins Bloomberg - Kimmel Institute for Cancer Immunotherapy (Baltimore, USA)  
**Valter Torri** - Istituto di Ricerche Farmacologiche Mario Negri - IRCCS (Milano, Italy)  
**Giorgio Trinchieri** - National Cancer Institute (Bethesda, USA)  
**Claudio Tripodo** - Università degli Studi di Palermo (Palermo, Italy)

13:00 Connection to the virtual meeting

13:45 Welcome addresses

### SESSION 1. COVID-19 AND CANCER (NIBIT-AIOM JOINT SESSION)

*Discussants: Matteo Bellone, Giuseppe Di Lucca, Alessandra Gennari, Claudio Tripodo*

14:00 **Claudio Doglioni** (Milano, Italy)  
*COVID-19 seen by a pathologist*

14:20 **Valter Torri** (Milano, Italy)  
*COVID-19 in lung cancer*

14:40 **Maria Rescigno** (Milano, Italy)  
*Microbiota, COVID susceptibility and cancer*

15:00 **Andrea Alimonti** (Bellinzona, Switzerland)  
*TMPRSS2 in prostate cancer and COVID-19*

15:20 Discussion

15:40 End of Session 1

### SESSION 2. B CELLS IN COVID-19 AND CANCER

*Discussants: Vincenzo Barnaba, Mario Paolo Colombo, Paolo Dellabona*

15:50 **Silent Poster Trailer A**

16:00 **Antonio Lanzavecchia** (Milano, Italy)  
*Antibody response in COVID-19*

16:20 **Catherine Sautes-Fridman** (Paris, France)  
*TLS as pillar of cancer immunity*

16:40 Discussion

17:00 End of Session 2

### SESSION 3. INNATE IMMUNITY IN COVID-19 AND CANCER (NIBIT-SIICA JOINT SESSION)

*Discussants: Giulia Casorati, Marco Cassatella, Vincenzo Russo, Antonio Sica*

17:10 **Silent Poster Trailer B**

17:20 **Vincenzo Bronte** (Verona, Italy)  
*Innate immune cells in COVID-19 and cancer*

17:40 **Karin de Visser** (Amsterdam, Netherlands)  
*Dissecting cancer cell-intrinsic mechanisms dictating the immune landscape of metastatic breast cancer*


18:00 Discussion

18:20 End of Session 3

### NIBIT KEYNOTE LECTURE

*Chairman: Mario Paolo Colombo*

18:30 **Giorgio Trinchieri** (Bethesda, USA)  
*Exploiting the microbiome for the benefit of cancer patients*



**Poster Session 1.**

Discussant: **Matteo Bellone, Vincenzo Bronte, Mario Paolo Colombo, Antonio Rosato**

- 09:00 **Abbass Darwich** - Humanitas University (Milano, Italy)  
*Identification of CHI3L1 as a soluble immune checkpoint promoting resistance to HER2 targeted therapy by impairing NK cell cytotoxicity*
- 09:10 **Francesca Hofer** - Università degli Studi Verona (Verona, Italy)  
*The Disabled homolog 2 controls pro-metastatic activity of tumor-associated macrophages*
- 09:20 **Milena Perrone** - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)  
*Activating Transcription Factor 3 functionally reprograms the bone marrow niche to sustain breast cancer*
- 09:30 **Anna Pastò** - Humanitas Research Hospital (Rozzano - MI, Italy)  
*Host immunity regulates cancer cell stemness*
- 09:40 **Antonella Sistigu** - Università Cattolica del Sacro Cuore (Roma, Italy)  
*Type I IFN signaling as a driver of cancer stemness*
- 09:50 **Paola Trono** - Institute of Biochemistry and Cell Biology, CNR (Roma, Italy)  
*hMENA<sup>11a</sup> loss regulates PD-L1 expression by activating the viral sensor RIG-I and inflammatory response*
- 10:00 **Arianna Calcinotto** - IRCCS Ospedale San Raffaele (Milano, Italy)  
*CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism*
- 10:10 **Claudio Enriquez** - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)  
*Castration-induced SPARC down-regulation in stromal cells drives neuroendocrine differentiation of prostate cancer*

**Poster Session 2.**

Discussant: **Paola Nisticò, Vincenzo Russo, Antonio Sica**

- 10:25 **Francesco Manfredi** - Università Vita-Salute San Raffaele (Milano, Italy)  
*The T Cell Exhaustion Signature Can Guide the Identification of Patient-Derived, Tumor-Reactive TCRs and Promote TCR Gene Editing for AML*
- 10:35 **Chiara Porta** - Università del Piemonte Orientale "A. Avogadro" (Novara, Italy)  
*Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC*
- 10:45 **Roberto Ferrara** - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)  
*Circulating and tumour associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models*
- 10:55 **Anna Tosi** - Università degli Studi di Padova (Padova, Italy)  
*Multiplex Immunofluorescent analysis of Luminal B breast cancer (BC) immune microenvironment in patients treated with neoadjuvant chemotherapy and immunotherapy: results of the phase II GIADA trial*
- 11:05 **Giulia Galli** - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)  
*Lipid metabolism shapes the efficacy of immunotherapy in non small cell lung cancer patients*
- 11:15 **Roberta Zappasodi** - Memorial Sloan Cancer Kettering Centre (New York, USA)  
*CTLA-4 blockade drives Treg glucose metabolism and loss of functional stability in glycolysis - defective tumors*



**Poster Session 3.***Discussant: **Marco Bregni, Massimo Di Nicola, Pier Francesco Ferrucci***

- 11:30 **Gloria Delfanti** - IRCCS Ospedale San Raffaele (Milano, Italy)  
*Combinatorial adoptive immunotherapy with tumor-retargeted iNKT cells and local restimulation by nanotherapeutics for the dual targeting of cancer and tumor-supporting myeloid cells*
- 11:40 **Stefano Ugel** - Università degli Studi di Verona (Verona, Italy)  
*Baricitinib restrains the immune dysregulation in severe COVID-19 patients*
- 11:50 **Clement Anfray** - Humanitas Research Hospital (Rozzano - MI, Italy)  
*Polymeric nanocapsules loaded with Toll-like receptors ligands to reprogram*
- 12:00 **Sara Bulfamante** - Università degli Studi di Torino (Torino, Italy)  
*Chemotherapy, but not immune checkpoint blockade, rescues effector function of peripheral T cells from pancreatic cancer patients in response to tumor associated antigens*
- 12:10 **Beatrice Greco** - IRCCS Ospedale San Raffaele (Milano, Italy)  
*Overcoming tumor resistance induced by N-glycosylation boosts CAR T cell efficacy against solid malignancies*
- 12:20 **Cristina Maccalli** - Sidra Medicine (Doha, Qatar)  
*Deep characterization of "Off-the-Shelf" CD19-Chimeric Antigen Receptor (CAR) T Cells Using Umbilical Cord Blood as Source of T lymphocytes*

**VIRTUAL POSTER WALK**

- 12:30 on <https://www.nibit.org/congress/Meeting-Proceedings/index.php>

**SESSION 4. CYTOKINES AND COMPLEMENT IN CANCER AND COVID-19 (NIBIT-SIC JOINT SESSION)***Discussants: **Paola Allavena, Attilio Bondanza, Giulio Cavalli, Claudio Tripodo***

- 14:45 **Wolf-Herman Fridman** (Paris, France)  
*The double edge B cells*
- 15:05 **Paolo Ascierto** (Napoli, Italy)  
*Analogies between immune related adverse events in patients undergoing immunotherapy and cytokine storm in COVID-19*
- 15:25 Discussion
- 15:45 End of Session 4

**PEZCOLLER KEYNOTE LECTURE***Chairman: **Mario Paolo Colombo***

- 15:50 **Enzo Galligioni** (Trento, Italy)  
*The Pezcoller Foundation*
- 16:00 **Drew Pardoll** (Baltimore, USA)  
*Applying the MANAFEST platform to analyze neoantigen-specific and coronavirus-specific T cell responses at the clonal level*





**SESSION 5. UPDATES IN CANCER IMMUNOTHERAPY (NIBIT-ACC JOINT SESSION)***Discussants: Marco Bregni, Pier Francesco Ferrucci, Ann Leen, Concetta Quintarelli*

- 16:45 **Suzanne Topalian** (Baltimore, USA)  
*A role and rationale for neoadjuvant immune checkpoint blockade in cancer therapy*
- 17:05 **Cliona Rooney** (Houston, USA)  
*Improving the function and persistence of CAR-modified T-cells in patients*
- 17:25 Discussion
- 17:45 End of Session 5

**SESSION 6. AT THE FOREFRONT OF TECHNOLOGY***Discussants: Vincenzo Bronte, Massimo Di Nicola, Paola Nisticò, Antonio Rosato*

- 17:50 **Raza Ali** (Cambridge, UK)  
*Imaging mass cytometry to understand how cells organise in the breast tumour microenvironment*
- 18:10 **Cristophe Mollet** (Promega Corporation, Madison, USA)  
*Advanced Microsatellite Instability (MSI) in Immunotherapy*
- 18:20 **Dario Armando Leone** (Miltenyi Biotec, Bergisch Gladbach, Germany)  
*Fully integrated solutions in inflammation and cancer research*
- 18:30 **Alexandre Darmoise** (Nanostring, Seattle, USA)  
*A Revolution in Spatial Biomarker Discovery - Morphology-guided Tissue Profiling at the Whole Transcriptome scale with GeoMx™ DSP*
- 18:45 Discussion
- 19:00 End of Session 6
- 19:00 **NIBIT AWARDS**
- 19:15 **Adjourn**





# NIBIT USEFUL INFORMATION

**If you wish to become a member of NIBIT Association, please visit**

[https://www.nibit.org/iscrizioni\\_nibit.php](https://www.nibit.org/iscrizioni_nibit.php)

The rate is € 50,00 / year

## COMPETITION AND PRICE

Applicants <40 years of age with an abstract accepted by the Scientific Committee will be considered for the "NIBIT BASIC SCIENCE AWARD" (€ 1.000,00) and for the "NIBIT TRANSLATIONAL SCIENCE AWARD" (€ 1.000,00) and for "NIBIT CLINICAL SCIENCE AWARD" (€ 1.000,00)

## ORGANISING SECRETARIAT



**Achelois - Professional Congress Organiser**

Via Larga 8 - 20122 Milano

Tel. 02 2643 2454

e-mail: [elena.delboca@achelois.eu](mailto:elena.delboca@achelois.eu)

ACHELOIS - Professional Congress Organiser

